SCHEMBL1179159

SCHEMBL1179159

CCN(CC)c1nc(C)cc(-c2nc(-c3cc(C)nc(C)c3)no2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 9/20 0.38
S1PR3 Q99500 6/20 0.38
TDP1 Q9NUW8 2/20 0.36
POLB P06746 1/20 0.35
NPC1 O15118 2/20 0.35
ALDH1A1 P00352 2/20 0.35
RAB9A P51151 2/20 0.35
MAPT P10636 4/20 0.34
NR1H4 Q96RI1 1/20 0.34
KDM4E B2RXH2 2/20 0.33
LMNA P02545 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
HSD17B10 Q99714 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
GAA P10253 1/20 0.33
MAP3K12 Q12852 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1179435 0.92 S1PR1 (0.36) S1PR1S1PR3TDP1POLBNPC1
SCHEMBL1179422 0.89 GRM5 (0.39) S1PR1S1PR3TDP1POLBNPC1
SCHEMBL1179764 0.88 S1PR1 (0.34) S1PR1S1PR3NPC1ALDH1A1RAB9A
SCHEMBL1179632 0.84 S1PR1 (0.35) S1PR1S1PR3POLBNPC1ALDH1A1
SCHEMBL3084808 0.84 S1PR1 (0.46) S1PR1S1PR3
SCHEMBL1179102 0.83 S1PR1 (0.33) S1PR1S1PR3NPC1ALDH1A1RAB9A
SCHEMBL3086366 0.82 S1PR1 (0.40) S1PR1S1PR3TDP1POLBNPC1
SCHEMBL3084222 0.82 S1PR1 (0.51) S1PR1S1PR3POLBNPC1ALDH1A1
SCHEMBL1179054 0.82 GRM5 (0.36) S1PR1S1PR3POLBNPC1ALDH1A1
SCHEMBL3086037 0.80 S1PR1 (0.41) S1PR1S1PR3POLBNPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046170-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2011-02-24 US claimed
EP-2262800-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-12-22 EP claimed
WO-2009109907-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-09-11 WO claimed
US-20110046170-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2011-02-24 US disclosed
EP-2262800-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-12-22 EP disclosed
WO-2009109907-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046170-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES TYMP, DPYD, ENTPD5 S1PR1 766/4885S1PR3 709/4885TDP1 698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.